Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expected to Earn Q1 2024 Earnings of ($0.88) Per Share

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 28th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.88) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.63) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2024 earnings at ($0.92) EPS, Q3 2024 earnings at ($0.96) EPS, Q4 2024 earnings at ($1.01) EPS and FY2028 earnings at ($0.94) EPS.

Separately, JMP Securities assumed coverage on shares of Acrivon Therapeutics in a research note on Friday, March 1st. They issued a “mkt outperform” rating and a $14.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $22.14.

Acrivon Therapeutics Price Performance

ACRV stock opened at $7.15 on Friday. The company has a market capitalization of $158.66 million, a PE ratio of -2.68 and a beta of 1.70. Acrivon Therapeutics has a 12 month low of $3.19 and a 12 month high of $14.39. The firm’s 50-day moving average is $4.63 and its 200 day moving average is $5.48.

Institutional Trading of Acrivon Therapeutics

Institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund bought a new stake in shares of Acrivon Therapeutics in the 1st quarter valued at about $28,000. Citigroup Inc. boosted its stake in Acrivon Therapeutics by 1,281.2% in the 2nd quarter. Citigroup Inc. now owns 2,790 shares of the company’s stock worth $36,000 after purchasing an additional 2,588 shares in the last quarter. California State Teachers Retirement System purchased a new position in Acrivon Therapeutics during the 1st quarter worth approximately $41,000. Wells Fargo & Company MN raised its position in Acrivon Therapeutics by 108.1% during the 2nd quarter. Wells Fargo & Company MN now owns 3,305 shares of the company’s stock worth $43,000 after buying an additional 1,717 shares during the last quarter. Finally, Barclays PLC purchased a new position in Acrivon Therapeutics during the 4th quarter worth approximately $47,000. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.